Epitope determination of immunogenic proteins of *Neisseria gonorrhoeae*

Daniel O. Connor1*, Lena Danckert1, Sebastian Hoppe1, Frank F. Bier2,3, Markus von Nickisch-Rosenegk1

1 Department of Molecular and Cellular Bioanalytics, Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses, Potsdam, Germany, 2 Institute of Biochemistry and Biology, University of Potsdam, Potsdam, Germany, 3 Department of Automation, Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses, Potsdam, Germany

*Daniel.Connor@izi-bb.fraunhofer.de

Abstract

*Neisseria gonorrhoeae* is the causative organism of gonorrhoea, a sexually transmitted disease that globally accounts for an estimated 80 to 100 million new infections per year. Increasing resistances to all common antibiotics used for *N. gonorrhoeae* treatment pose the risk of an untreatable disease. Further knowledge of ways of infection and host immune response are needed to understand the pathogen-host interaction and to discover new treatment alternatives against this disease. Therefore, detailed information about immunogenic proteins and their properties like epitope sites could advance further research in this area. In this work, we investigated immunogenic proteins of *N. gonorrhoeae* for linear epitopes by microarrays. Dominant linear epitopes were identified for eleven of the nineteen investigated proteins with three polyclonal rabbit antibodies from different immunisations. Identified linear epitopes were further examined for non-specific binding with antibodies to *Escherichia coli* and the closely related pathogen *Neisseria meningitidis*. On top of that, amino acids crucial for the antibody epitope binding were detected by microarray based alanine scans.

Introduction

*Neisseria gonorrhoeae* is one of two pathogenic species within the genus *Neisseria* and is the causative organism of the curable sexually transmitted disease (STD) gonorrhoea that is strictly limited to the human host. The pathogen appears as a gram-negative diplococcus and is, thus, often abbreviated as gonococcus. During infection, the bacteria colonize the urogenital epithelial cells. Since gonococcal infections are asymptomatic in up to 80% of women [1] and 10 to 40% in men [2,3], many patients remain untreated. In consequence, pelvic inflammatory disease (PID) occurs in up to 40% of untreated women [4]. Furthermore, the infection can lead to sterility in men and infertility in women [1]. The WHO estimates up to one million sexually transmitted nonviral infections per day [5]. *N. gonorrhoeae* accounts for more than 20% of those infections. Furthermore, a report from the Centers for Disease Control and Prevention (CDC) published in 2014 stated that the three major bacterial STDs have shown substantial
increase rates since 2013: Gonorrhoea 5.1%, Chlamydia 2.8% and Syphilis 15.1% [6]. Although reports of STDs can be found in a lot of ancient texts [7], STDs have never been extinguished fully, they have rather been merely controlled during the last decades by the use of antibiotics. Since the advent of antibiotics, however, \textit{N. gonorrhoeae} has developed resistances against the majority of commonly used antibiotics leading to a potentially untreatable pathogen in the future [8–11]. The current guidelines from the CDC and the European guideline on the diagnosis and treatment of gonorrhoea in adults recommend the combination of oral azithromycin and injectable ceftriaxone as the last remaining first-line treatment [12,13]. Thus, it is paramount to expand the arsenal in available treatment options sooner rather than later, before the aforementioned antibiotics become ineffective. Hence, a deeper insight into the immunogenic and virulence-associated proteins of \textit{N. gonorrhoeae} might help to unveil novel treatment options and nurture new diagnostic devices. We have previously identified six novel immunogenic proteins of \textit{N. gonorrhoeae} via phage display while also verifying the immunogenic character of thirteen additional proteins [14]. These proteins were found to be involved in important processes of the pathogens metabolism rendering them highly attractive to our purpose. Therefore, further investigation of the identified proteins is of high relevance.

Consequently, for the present study, those previously identified proteins were investigated for linear epitopes and identified epitopes were subsequently characterised by specificity assays and alanine scans. Epitopes might be utilised for the generation of specific antibodies or for vaccination [15]. By identifying linear epitopes potential vaccine candidates have already been obtained for \textit{Staphylococcus aureus} [16], \textit{Klebsiella pneumoniae} [17] or the dengue virus [18] amongst others. Since the proteins were presented as polypeptide fragments on the phage surface and not as full-length proteins, only the former were analysed, thus significantly reducing the number of overlapping peptides needed for epitope mapping. Additionally, as those polypeptides were originally isolated due to their immunogenic character, it can be safely assumed that the fragments contain the epitope sites.

Results

Epitope mapping

Epitope mappings were conducted on microarray slides for all proteins except NGO0170 which was conducted on a cellulose membrane. Based on previously performed phage display analysis polypeptide segments of corresponding proteins were selected and the results are summarized as box-and-whisker plots. These were calculated from merged data obtained by incubation with three different polyclonal rabbit antibodies to \textit{N. gonorrhoeae} and three replicates of the immobilised peptide per incubated subarray (n = 9). Results of the specificity controls are given in the supplementary figures (S1 Fig, S2 Fig). Table 1 lists all of the previously identified proteins, states the regions used for epitope mapping, and summarizes the identified epitope sequences [14]. Additionally, the results of the epitope mappings are split evenly between Fig 1 and Fig 2. The former covers epitopes of NGO0326, NGO0564, NGO0592, NGO0777, NGO1429, and NGO1577, while the latter summarizes epitope mappings of NGO1656, NGO1852, NGO2094, NGO2095 polypeptides 1 and 2, NGO2095 polypeptide 4 as well as NGO0170, which was the only epitope mapping to be conducted on a cellulose membrane. The epitope mappings of the remaining proteins featured in Table 1, namely NGO0584, NGO0642, NGO0916, NGO0983, NGO1043, NGO1634, NGO1796, and NGO2139 resulted either in very low signal intensities in the range of the negative control or high variance. Thus, the results are not shown here as no reliable linear epitope sites could be identified in these cases. Specificity controls were generally in the range of the negative controls for the polyclonal antibodies to \textit{E. coli} and \textit{N. meningitidis}. However, a few exceptions to this were observed. For
peptide 0592_2_3 incubation with *N. meningitidis* antibody led to signal intensities of approximately 25% as compared to the specific interaction. Peptide 1429_3_1 (AGLSTGDIDDVILVG) harboured approximately 10% of the signal intensity of the original signal for the *E. coli* antibody (S1E Fig). The specificity assays for all peptides of NGO2095 displayed no non-specific interaction except for 2_12 and 2_13 with 16% and 10% of the original intensity after incubation with the anti-*N. meningitidis* antibody.

Table 1. Immunogenic proteins identified by phage display in a previous work [14].

| *N. gonorrhoeae* locus tag | Protein name | Predicted localisation | Region used for epitope mapping and total length of amino acid sequence | Identified epitope peptide number and sequence |
|---------------------------|--------------|------------------------|---------------------------------------------------------------------|-----------------------------------------------|
| NGO0170 | ABC transporter, ATP-binding protein | Cytoplasmic membrane | 205–245 (251) | Peptide 1_3 | LILAREKIAAGATETI |
| NGO0326 | RNA-binding protein Hfq | Cytoplasm | 57–93 (97) | Peptide 1_5 | QHENKPQPAPASTLY |
| NGO0564 | dihydrolipoamide acetyltransferase | Cytoplasm | 3–106 (539) | Peptide 1_1 | IVEIKVPOIGGHENV Peptide 1_23 | AEAQPAPAAAGGATY |
| NGO0584 | 50S ribosomal protein L9 | Cytoplasm | 38–81 (150) | - |
| NGO0592 | trigger factor | Cytoplasm | 111–149; 239–286 (437) | Peptide 2_3 | LPEVDADFARALSIA |
| NGO0642 | tRNA pseudouridine synthase B | Cytoplasm | 1–88 (306) | - |
| NGO0777 | DNA-binding protein Hu | Cytoplasm | 4–37 (89) | Peptide 1_6 | KALDATTTNAVNLK |
| NGO0916 | dihydrolipoamide succinyltransferase | Cytoplasm | 1–91 (393) | - |
| NGO0983 | outer membrane protein H.8 | Outer membrane | 23–80 (88) | - |
| NGO1043 | hypothetical protein | Periplasm | 35–88 (114) | - |
| NGO1429 | molecular chaperone DnaK | Cytoplasm | 144–166; 209–269; 328–379; 517–592 (642) | Peptide 1_3 | QATKDAegisAGLDVYK Peptides 2_9 | IDEFKKEQGIDLKO Peptide 3_7 | EAVKDFGGKEPRKDV |
| NGO1577 | outer membrane protein PIII | Outer membrane | 76–142; 182–220 (236) | Peptide 1_2 | VEGAPQPSVLTISLS Peptide 1_9 | AEAQNPLKLTVLQL |
| NGO1634 | hypothetical protein, putative phage associated protein | Cytoplasm | 116–148 (183) | - |
| NGO1656 | conserved hypothetical protein | Unpredictable | 1–44 (288) | Peptide 1_9 | KIDSSVIDAQVAAFR |
| NGO1796 | ribosome recycling factor | Cytoplasm | 32–130 (185) | - |
| NGO1852 | 50S ribosomal protein L7/L12 | Unpredictable | 26–71 (123) | Peptide 1_4 | VNVAPAGAGAADAE |
| NGO2094 | chaperonin 10 kDa subunit | Cytoplasm | 6–71 (96) | Consensus of peptides 3 and 4 EKRTAGTVLPE Peptide 1_11 | EKRTAGTVLPE |
| NGO2095 | chaperonin 60 kDa subunit | Cytoplasm | 33–55; 145–231; 301–401; 440–521 (544) | Peptide 1_1 | FKKNVVDRAFG Consensus of peptides 2_3 and 2_4 | DEQG3AIAAA Peptide 2_13 | FDRGNYLSPYFI Peptide 4_10 | YGNAGGGEYGMAG Peptide 4_14 | GVDVAPKVRSLAQH |
| NGO2139 | genome-derived Neisseria antigen 1946 | Cytoplasmic membrane | 123–231 (288) | - |

Only those parts of each protein presented on the phage surface were examined for epitopes by epitope mapping.

https://doi.org/10.1371/journal.pone.0180962.t001
Fig 1. Epitope mapping (n = 9) of the polypeptides of A) NGO0326, B) NGO0564, C) NGO0592, D) NGO0777, E) NGO1429, F) NGO1577. The boxes embody 50% of the values, while the whiskers comprise 98% of the data. Outliers are marked with a small x. Median values are indicated as a horizontal line, while the mean values are marked by a small square. Myelin basal protein (MBP) and rabbit Immunoglobulin G (IgG) were included as negative (red) and positive (green) controls. If two or more polypeptides of one protein were examined, boxes are coloured blue for peptides of polypeptide 1, black for the second polypeptide and orange for the third polypeptide.

https://doi.org/10.1371/journal.pone.0180962.g001
Fig 2. Epitope mapping (n = 9) of the remaining polypeptides. A) NGO1656, B) NGO1852, C) NGO2094, D) NGO2095 polypeptides 1 and 2, E) NGO2095 polypeptide 4, F) NGO0170 via cellulose membrane (Lot# 3542_1). A)–E) The boxes embody 50% of the values, while the whiskers comprise 98% of the data. Outliers are marked with a small x. Median values are indicated as a horizontal line, while the mean values are marked by a small square. Myelin basal protein (MBP) and rabbit Immunoglobulin G (IgG) were included as negative (red) and positive (green) controls. If two polypeptides of one protein were examined boxes are coloured blue for peptides of polypeptide 1 and black for the second polypeptide. F) Colour signals were inverted and analysed by GenePix Pro 7 and visualised as histogram.

https://doi.org/10.1371/journal.pone.0180962.g002
Alanine scan

All identified epitopes summarized in Table 2 were further characterized by alanine scan to determine amino acids that are critical for antibody-epitope binding. Considerable drops of signal intensity upon substitution with alanine indicate crucial amino acids for binding of the antibody to its epitope. The results of the alanine scans are included in Table 2 with additional information about the conservation of the epitope sequence. The corresponding Box-Whisker-Plots can be found in the supplementary figures (S3 Fig, S4 Fig and S5 Fig).

The alanine scan results can be divided into five groups. Various amino acid substitutions in the sequences of the identified epitopes resulted in signal decreases of more than 90% compared to the mean signal intensities of the remaining peptides. The epitopes of the first group are conserved in the genus *Neisseria* or on species level and showed signal decreases > 90% for substitutions of certain amino acids. This was true for NGO1577_1_9, NGO1852_1_4, NGO2095_4_10, NGO0777_1_6, NGO2094_1_3c and NGO2094_1_10c. The first two are both conserved in *N. gonorrhoeae* or *N. meningitidis* and contained five or four crucial

Table 2. Summary of the alanine scans to determine crucial amino acids for antibody-epitope binding.

| Name               | Original sequence | Loss of binding upon substitution of residues | Conserved in (100% identity with BLAST) |
|--------------------|-------------------|-----------------------------------------------|----------------------------------------|
| NGO0777_1_6        | KALDATNAVTNALK    | D (Pos. 4) 96%, T (Pos. 6) 99%                | Neisseria                               |
| NGO1577_1_9        | AEAQNKLQVGLQRLS   | E (Pos. 2) 99%; D (Pos. 5) 61%; N (Pos. 6) 99%; L (Pos. 10) 63%; R (Pos. 13) 99% | *N. gonorrhoeae, N. meningitidis*      |
| NGO1852_1_4        | VAVAGEAGAGAAAEE   | P (Pos. 6) 82%; G (Pos. 8) 78%; G (Pos. 10) 90%; D (Pos. 13) 72% | *N. gonorrhoeae, N. meningitidis*      |
| NGO2094_1_3c       | EEKTQIGVLP        | T (Pos. 4) 88%; S (Pos. 6) 76%; G (Pos. 7) 97% | Neisseria                               |
| NGO2094_1_10c      | GRIKGDGARRP       | I (Pos. 3) 90%; R (Pos. 9) 97%               | Neisseria                               |
| NGO2095_4_10       | YGYNAGSEYDMIG     | E (Pos. 9) 99%                               | *N. gonorrhoeae*                        |
| Conservation in *N. gonorrhoeae* or *N. meningitidis* and signal decreases > 90% |
| NGO0564_1_1        | IVEIKVDIGGHEV     | DIGHG (Pos. 8–12) 99%                        | Neisseriaceae                           |
| NGO1429_1_3        | DAGRIAGLDVK       | GLD (Pos. 7–9) and K (Pos. 11) 99%; V (Pos. 10) 83% | Bacteria                               |
| NGO1429_3_7        | EAVRDFGKPEKRDV    | D (Pos. 5) 90%; F (Pos. 6) 95%; F (Pos. 7) 99%; G (Pos. 8) 90% | Proteobacteria                          |
| NGO2095_2_13c      | FDRGYLSPYFYI      | D (Pos. 2) 99%; GY (Pos. 4 and 5) 99%; L (Pos. 6) 84%; SP (Pos. 7 and 8) 99% | Bacteria                               |
| Conserved in the kingdom bacteria or family Neisseriaceae and signal decreases > 90% |
| NGO0326_1_5        | QUEKIKQAPASTLV    | A (Pos. 8) 67%, A (Pos. 9) 63%, L (Pos. 14) 83% | *Neisseria gonorrhoeae*                |
| NGO0564_1_23       | AEAQAPPAAAGGATV   | P (Pos. 7) 52%; G (Pos. 11) 63%; T (Pos. 14) 79% | *Neisseria gonorrhoeae*                |
| NGO1577_1_2        | VEQAPVYDDETISLS  | Q (Pos. 3) 68%; A (Pos. 4) 63%              | *N. gonorrhoeae, N. meningitidis*      |
| Conserved in the order Neisseriales or the family Neisseriaceae and signal decreases < 90% |
| NGO0592_2_3        | LPEVADFAKALGIA    | D (Pos. 5) 70%                               | Neisseriales                            |
| NGO2095_1_1        | PFRRNVVDRAGF      | D (Pos. 9) 53%; R (Pos. 10) 71%              | Neisseriaceae                           |
| NGO2095_2_3c       | DEQVAIGAE        | G (Pos. 5) 75%; I (Pos. 7) 88%               | Neisseriaceae                           |
| Ambiguous results or no quantification applicable |
| NGO0170_1_3        | LLAREKIAAGATETI   | No quantitative evaluation possible           | Neisseria                               |
| NGO1656_1_9        | SVIDAQVAAR       | low overall signal intensities                | Neisseria                               |
| NGO2095_4_14       | GVLDPAKTSALQR     | No considerable loss of binding               | Neisseriaceae                           |

Epitopes are named by their protein origin, the polypeptide region and the peptide which was determined as epitope site. Consensus sequences are labelled with c. Crucial amino acids are underlined in the original sequence and listed in the third column with their percentage loss in comparison to the mean value of the remaining peptides. Furthermore, conservation of the epitope sequence shows the specificity of the epitope region. BLAST results with 100% query cover and 100% identity were defined as conservation parameter.

https://doi.org/10.1371/journal.pone.0180962.t002
residues. NGO2095_4_10 is solely conserved in *N. gonorrhoeae* and contains one crucial residue. The remaining three are all conserved in the genus Neisseria and substitution of individual amino acids led to an almost complete signal loss.

The second group merges the epitopes that showed signal decreases of > 90% and are conserved in the kingdom bacteria or the family Neisseriaceae and thus are not specific for *Neisseria*. These epitopes were NGO0564_1_1, NGO1429_1_3, NGO1429_3_7 and NGO2095_2_13c. All of these epitopes revealed a sequence of 4 to 5 consecutive amino acids where substitution of single amino acids led to an almost complete signal loss.

The third group consists of epitopes that are conserved in the species *N. gonorrhoeae* and *N. meningitidis* but substitutions of single amino acids resulted in signal decreases of < 90% compared to the mean signal intensities of the remaining peptides. This applied to NGO0326_1_5, NGO0564_1_23, and NGO1577_1_2. Substitution of amino acids led to a distinct signal decrease of 40–83%, although the signal drop was not as fundamental as for epitopes in group one and two.

The fourth group includes epitopes that are conserved in the order Neisseriales or the family Neisseriaceae and showed signal decreases < 90% during alanine scan. NGO0592_1_3, NGO2095_1_1 and NGO2095_2_3c fall into this category. The remaining epitopes, NGO1656_1_9 and NGO2095_4_14 showed ambiguous results and comprised group 5. Residues essential for binding could not be determined.

The alanine scan for NGO0170 was performed with immobilised peptides on a cellulose membrane (S6 Fig). Quantification was not equally applicable as colour spots show different intensities. Peptides 1 to 3 and peptides 7 to 10 showed a reduced colour reaction upon substitution. Those amino acids could be relevant for antibody binding. In addition, the epitope is part of a membrane-bound protein and conserved in the genus *Neisseria*.

**Mapping to protein models**

All identified epitopes and crucial amino acids for antibody binding were mapped to predicted protein models of each protein. Furthermore, the phage presented polypeptides that were identified in a previous work and investigated for epitope mapping are marked in the models. All models were checked by QMEAN for their reliability (Table 3). All QMEAN values lay above the cutoff of 0.4 except for the model of NGO1577. Additionally, Table 3 includes information about the closest structural homologues of each examined protein.

NGO0170 was predicted to be localised in the cytoplasmic membrane. The identified polypeptide was located at the C-terminal end of the protein spanning three α-helices and two β-sheets (Fig 3A). The epitope region was localised in the middle of the polypeptide and is highlighted in blue. The two determined crucial regions for antibody binding were located just before and after a loop. The closest structural homologue consists of two identical chains that are embedded in the membrane and two homologous chains of NGO0170 extending into the cytoplasm (Fig 4A). Likewise, the polypeptide of NGO0326 was located at the C-terminal end of the protein and encompassed a β-sheet and random coil structures (Fig 3B). The identified epitope was localised at the C-terminal end of the polypeptide. Alignments of all sequences of the structural homologues did not include the epitope’s sequence. Hence, only the monomeric model is shown. The identified polypeptide of NGO0564 had a length of 102 amino acids and was located at the N-terminal end of the protein (Fig 3C). Alignments of available structural homologues in the PDB database included only amino acids starting from residue number 287. Therefore, most of the polypeptide structure was modelled as random coil. The identified epitopes were located at the N-terminal end and one at the C-terminal end of the polypeptide. Both epitopes were located in that part of the structure model that was not covered by
alignments. Mapping of the epitope to the multimeric model was not applicable since the corresponding part was not covered by the homologous models. The two identified polypeptides of NGO0592 were located in the middle of the amino acid sequence (Fig 3D). The identified epitope included an α-helix and random coil structures. The identified polypeptide of NGO0777 was located at the N-terminal end of the protein (Fig 3E). Structural motifs of the polypeptide were largely α-helices. The epitope region and two crucial amino acids for antibody binding were located at the C-terminal end of the polypeptide. Epitopes were also identified in homodimeric model (Fig 4B). Four identified polypeptides for NGO1429 were located in different parts of the protein (Fig 3F and 3G). The two epitopes that were successfully analysed by alanine scans are highlighted in the multimeric model (Fig 4C). Most of NGO1577 secondary structure was modelled as random coil structure (Fig 3H). The obtained QMEAN value was 0.308 resulting in a free modelled protein target. The only epitope contained in the IEDB database was located separated from the examined polypeptides [31,32]. This epitope is coloured in dark green in the middle of the snap-shot of the protein model. The isolated polypeptide of NGO1656 was located at the N-terminal end of the protein and included an α-helix and random coil structures (Fig 3I). The identified epitope was determined at the C-terminal end of the polypeptide. The epitope was located at the bottom part when considering the snap-shot of the multimeric model (Fig 4D). The isolated polypeptide of NGO1852 stretched across three α-helices and one β-sheet in the middle of the protein’s primary structure (Fig 3J). The identified epitope is located in the middle of the phage presented polypeptide. The quaternary structure of the homologue is assembled with two identical subunits of the homologous protein of NGO1852 and another subunit (Fig 4E). Many different parts of both proteins NGO2094 and NGO2095 were identified as immunogenic polypeptides by phage display in a previous work. Hence, large parts of the proteins were examined for epitopes. The two identified epitopes of NGO2094 were located at the accessible outer regions of the protein (Fig 3K). Crucial amino acids for antibody binding were determined just before and behind the loops of

| Protein locus tag | QMEAN value | Closest structural homologue | PDB ID | Host organism | Quaternary structure | Epitope included in homologous structure | Reference |
|-------------------|-------------|-----------------------------|--------|---------------|---------------------|----------------------------------------|-----------|
| NGO0170          | 0.652       | ABC transporter             | 2NQ2   | Haemophilus influenza | heterotetramer       | yes                                    | [19]      |
| NGO0326          | 0.630       | Hfq                         | 4NL2   | Lysteria monocytogenes | homohexamer         | no                                     | [20]      |
| NGO0564          | 0.487       | catalytic domain of dihydrolipoamide acetyltransferase | 4N72   | Escherichia coli | homotramer         | no                                     | [21]      |
| NGO0592          | 0.618       | trigger factor protein       | 1W26   | Escherichia coli | monomer            | yes                                    | [22]      |
| NGO0777          | 0.586       | DNA binding protein         | 1P71/1P51 | Anabeana sp./ Staphylococcus aureus | homodimer         | yes                                    | [23,24] |
| NGO1429          | 0.675       | chaperone HSP70             | 4JNE   | Escherichia coli | homodimer            | yes                                    | [25]      |
| NGO1577          | 0.308       | metallopeptidase            | 3IUU   | Mesorhizbium sp. BNC1 | monomer        | no                                     | [26]      |
| NGO1656          | 0.414       | SurA-like chaperone         | 3RFW   | Campylobacter jejuni | homodimer           | yes                                    | Not published|
| NGO1852          | 0.560       | ribosomal protein L12       | 1DD3   | Thermogota maritima | heterotrimer         | yes                                    | [27]      |
| NGO2094          | 0.434       | mitochondrial chaperone/ GroEL-GroES complex | 4PJ1/1PCQ | Homo sapiens/ Escherichia coli | hetero-28-mer   | hetero-21-mer                          | [28,29] |
| NGO2095          | 0.734       | GroeEL protein              | 1KP8   | Escherichia coli | homo-14-mer        | yes                                    | [30]      |

https://doi.org/10.1371/journal.pone.0180962.t003
Fig 3. 3-dimensional monomeric structure models of the immunogenic proteins. Isolated polypeptides determined in a previous work are marked in orange, identified epitopes are highlighted in blue, amino acids crucial for antibody binding are coloured in green and individual amino acids are...
both epitopes. The two obtained multimeric structures of a chaperon complex differ mainly in number and localisation of the GroES chains. While GroES chains are assembled on both sides of the human protein, they are only associated on one side of the *E. coli* protein. Six epitope regions were identified for NGO2095 (Fig 3L). Most epitopes were accessible in the protein model and not buried inside. The identified six epitopes are coloured differently in the multimeric model (Fig 4H). Two epitopes (blue and pink) are presented on the surface of the protein model while the other epitopes seemed to be buried in the displayed X-ray diffraction snapshot.

**Discussion**

Nineteen immunogenic proteins of *N. gonorrhoeae* identified in a previous work [14] were examined for linear epitopes by microarray epitope mapping in this study. Identification of linear epitopes by peptide microarray is a well-established technique which has been applied
successfully for the determination of linear epitope regions from other human pathogens [33,34]. Distinct linear epitopes were identified with three polyclonal rabbit antibodies for 11 of the examined 19 proteins. Hence, the identified epitopes appear to possess an immunodominant character that is recognised and processed by the immune response of individual groups of experimental animals, namely rabbits. Notably, linear epitopes were identified for 58% of the examined proteins, contrary to the general occurrence of linear epitopes (10%) compared to structural epitopes (90%) in nature [35]. This high number of identified linear epitopes arose most likely through the preceding selection of phage presented polypeptides, since most presented polypeptides represent only partial regions of the corresponding full-length protein. Therefore, tertiary and quaternary structures are most likely not formed as in the full-length protein so that linear epitopes are bound by immobilised antibodies to a higher extent and amplified through consecutive panning rounds. Novel linear epitopes of specific antigens could play an essential role for the development of diagnostics or suitable vaccines [15,36] e. g. for the generation of monoclonal antibodies which than could be applied in a diagnostic test or as part of a vaccine used for active or passive immunisation. For both applications specific targets are crucial. Hence, we examined potential cross reactivities to N. meningitidis and E. coli antibodies which resulted in specific binding for most of the identified epitopes. Only two epitopes, NGO0592_1_3 (LPEVDAFDKALGA) and NGO2095_2_13c (DEQVGAIIAEAA) showed partial non-specific binding after incubation with the anti-N. meningitidis antibody. Non-specific binding amounted to 25% and 10% compared to the original signals. All identified linear epitope sequences were checked for conservation by BLAST using blastp suite. Homology of NGO0592_1_3 was high throughout many species of Neisseriales including N. meningitidis with 100% identity. NGO2095_2_13c was conserved among many bacteria (see Table 2). On the contrary, NGO0326_1_5, NGO0564_1_23 and NGO2095_4_10 showed alterations in their sequence even for closely related organisms like N. meningitidis and other Neisseria species, indicating highly specific epitope regions for N. gonorrhoeae. These bioinformatic findings concur with the experimental results that entailed no binding to antibodies reactive to other bacteria. The other epitopes were conserved either in N. gonorrhoeae and N. meningitidis, Neisseria, Neisseriaceae or Neisseriales. Three identified epitopes (NGO1429_1_3, NGO1429_3_7 and NGO2095_2_13c) were conserved in the phylum of Proteobacteria or in all bacteria.

Epitope mappings for NGO0584, NGO0916, NGO1043, NGO1634 and NGO1796 only showed distinct linear epitopes for the antibody used for the initial screenings of the DNA phage libraries (data not shown). However, incubation with three antibodies yielded widely varying signal intensities although all three polyclonal antibodies were capable to detect the corresponding full-length proteins in a previous study [14]. Presumably, the full-length proteins are immunodominant, however, the polyclonal immune response was triggered by different epitopes. Therefore, it is conceivable that different epitope regions were predominantly addressed by the polyclonal antibody solutions that were obtained through various immunisations. Consequently, individual epitope regions during epitope mapping are not recognised by each of the polyclonal antibody solutions, while the intact full-length proteins are. Hence, although the five full-length proteins showed immunodominant character, the herein identified epitopes did not appear to be immunodominant. In contrast, epitope mapping of the examined part of NGO0983 showed increased signal intensities for seven of the twelve overlapping peptides compared to the negative control (data not shown). NGO0983 is annotated as outer membrane protein H.8 that is built up by a tandem repeat of the sequence AAEE in which “e” is either Alanine or Proline. Binding regions of the polyclonal antibodies were thereby located in the tandem repeat area. All identified epitopes found in this study have not been described in literature before. However, different epitope regions of some examined
proteins had been deposited at the IEDB database: a homologous protein of NGO0564 (N. meningitidis T-cell epitope DDTLITLETDKATM [37]), NGO0916 (T-cell epitope DEULTDLKVT [37]), a homologue of the repetitive protein NGO0983 (N. meningitidis B-cell epitope EATPAEAPEASEAPAEAAP [38]) and NGO1577 (B-cell epitope WKNAYFDK [32]). The bigger part of the examined proteins was predicted to be located in the cytoplasm and hence, epitope accessibility for detection and antibody binding would be hampered. Yet, several of these cytoplasmic proteins were found to be surface exposed (e.g. homologue of NGO1852 [39], compare Connor et al. [14]) which results in intriguing targets for further investigations.

Subsequent examination of the identified epitope regions ought to provide an indication of the suitability of these peptides for therapeutic or diagnostic purposes. Therefore, recombinant monoclonal antibodies need to be generated against the epitope peptides and the potential to detect intact or lysed bacterial cells ought to be investigated. Antibodies capable of detecting or flagging the bacterial cell could well be applied to the development of a potential therapeutic tool or serve as a novel therapeutic approach. As compared to recombinant protein production, short epitope peptides benefit from their easy and fast fabrication in large quantities via peptide synthesis. Thus, the identified epitopes could be utilised for serological screenings, if they prove to be immunodominant in humans. Furthermore, epitope peptides have been successfully used for the development of vaccines before [15]. Nevertheless, the results presented herein, were generated using rabbit sera only, leaving a number of aspects to be investigated for further conclusions.

Material and methods

Antibodies

Three different polyclonal rabbit antibodies against N. gonorrhoeae (Acris BP1050 Lot# 2B04511 and Lot# 7A03112; Abcam ab19962 Lot# GR204640-1) were deployed as primary antibodies individually for microarray experiments. One of those polyclonal antibodies (Acris BP1050 Lot# 2B04511) was used for the approaches with cellulose membranes. Polyclonal rabbit antibodies to Escherichia coli (Abcam 137967 Lot# GR129883-2) and Neisseria meningitidis (AbD Serotec 6600–5906 Lot# 281111) were used to examine specificity of the epitope sites. All polyclonal rabbit antibodies mentioned before were generated by immunisation of whole inactivated cells and subsequent purification by protein A chromatography and were commercially available as polyclonal IgG antibodies. A polyclonal goat antibody to rabbit IgG conjugated with Chromeo546 (Abcam ab60317 Lot# GR35519-8) was applied as a secondary antibody in the microarray experiments enabling a fluorimetric readout. A polyclonal goat antibody to rabbit IgG conjugated with HRP (Abcam, ab6721, Lot# GR3175-3) was used as secondary antibody for the cellulose membrane approach.

Epitope mapping by microarray technique

Immunogenic proteins that have been identified by phage display in a previous work [14] were used for epitope mapping (Table 1). The polypeptide fragments presented during phage display were divided into overlapping 15-mer oligopeptides in silico with an overlap of eleven and an offset of four amino acid residues. If more than one polypeptide fragment per protein had been identified during phage display, each part was used independently for oligopeptide generation. Peptide synthesis and coupling to microarray slides was conducted by JPT Peptide Technologies GmbH. Microarray slides featured three identical subarrays, with each peptide present as a triplicate per subarray. Incubation was performed by applying a Proplate 3-well
chamber system to enable individual incubation of each subarray with different antibodies in parallel, resulting in n = 9 replicates for each examined peptide.

The slides were blocked initially with 2% dried milk powder in phosphate buffered saline (PBS) with 0.05% Tween-20 (MPBST) for 3 h, washed five times with PBS with 0.05% Tween-20 (PBST) and incubated with appropriate primary antibodies at 4°C overnight with gentle agitation (40 rpm), followed by a washing step before the secondary antibody was applied for 2 h in the dark at 40 rpm. The slides were washed three times with PBST and rinsed with a constant flow of H$_2$O$_{dest}$. Subsequently, the slide was dried by nitrogen flow and scanned. The same incubation procedure was used as a control for non-specific secondary antibody binding except that the primary antibody was replaced by PBS during incubation. An Axon GenePix 4300A laser scanner (Molecular Devices) was used for scanning the incubated slides. The scanner was operated with the following settings: 532 nm laser, PMT gain 400, 40% laser power, lines to average 1, 10 μm resolution and standard green emission filter at 532 nm. In parallel, potential epitope peptides and surrounding peptides with increased signal intensities compared to the other peptides were examined for non-specific binding with polyclonal antibodies to *E. coli* and *N. meningitidis*.

**Alanine scan**

Individual peptides and consensus sequences of consecutive peptides showing distinct signal intensities during epitope mapping were chosen for subsequent alanine scan. The modified peptides were produced and immobilised onto glass slides by JPT Peptide Technologies GmbH. The array design was identical to the epitope mapping, featuring three identical subarrays with each peptide in triplicate per subarray. Incubation procedure, scanning and analysis were performed as described above for epitope mapping.

**Microarray analysis**

The median of the fluorescence intensity of each spot was used for microarray analysis. Each spot was corrected by its local background (median F532 − B532). Signals of the control chamber (PBS and secondary antibody) were subtracted from the corresponding spot signals incubated with primary and secondary antibody to obtain relative fluorescence intensities (RFI) and to exclude non-specific binding of the secondary antibody.

**Epitope mapping and alanine scan via cellulose membrane**

The epitope mapping and alanine scan of NGO0170 were performed with cellulose membranes instead of using microarray technique. The phage presented polypeptide (identified in previous work) was divided into peptides of 15 amino acids in length equivalent to the microarray epitope mapping. Peptide synthesis was conducted by JPT Peptide Technologies GmbH directly on the cellulose membrane. Incubation of the membranes for both epitope mapping and alanine scan were performed as follows. All incubation steps were carried out on a horizontal shaker at 40 rpm. First, the membrane was incubated with methanol for 5 min, followed by 3 x 3 min washing with TBS-T (50 mM Tris, 137 mM NaCl, 2.7 mM KCl, pH 8.0 adjusted with HCl, 0.05% Tween 20). Subsequently, the membrane was blocked with 2% skim milk powder in TBS-T (2% MTBS-T) at 4°C overnight or for 2 h at room temperature. Next, the membrane was incubated with 4 μg mL$^{-1}$ of the primary antibody for 3 h and washed with TBS-T (3 x 5 min). Thereupon, the membrane was incubated with 1 μg mL$^{-1}$ of secondary antibody for 2 h. Antibody binding was detected by incubation with substrate (0.1% 3,3’-Diaminobenzidin (DAB) in TBS, pH 7.3, 100 mM Imidazol, 0.01% H$_2$O$_{per}$) for 10 min. Subsequently, the membrane was washed with water (3 x 10 min) and incubated in H$_2$O$_{dest}$ overnight to decrease the background. Colour
intensities were analysed by inverting the image and using GenePix Pro 7. The identified peptide region was further characterized by alanine scan. The alanine scan was conducted with the same parameters as the epitope mapping.

Bioinformatics

Localisation prediction was performed with PSORTb v3.0.2 [40]. Visualisation and editing of sequence data was carried out with Geneious Pro 6.1.8. Identified epitopes were compared to deposited epitopes in IEDB database [31]. 3-dimensional structures were predicted using I-TASSER [41–43] and models were visualised with Chimera [44]. Predicted models were selected by their C-score, which is a confidence score used by I-TASSER to estimate the quality of a predicted model. The C-score usually ranges between −5 and 2. Higher C-score values represent models with a higher confidence. The model reliability was additionally checked by QMEAN [45]. Models with QMEAN values < 0.4 are considered to be free modelled targets, while QMEAN values > 0.4 are regarded to be template based models [46]. Linear epitope sequences were checked for conservation by BLAST [47]. Evaluation of results was performed by Microsoft Excel and OriginPro 9.1 G (Originlab).

Supporting information

S1 Fig. Specificity controls of the identified peptides with epitope features of A) NGO0326, B) NGO0564, C) NGO0592, D) NGO0777, E) NGO1429, F) NGO1577. Almost all peptides showed specific binding for anti-N. gonorrhoeae antibodies. Only two peptides of NGO0592 (C) showed unspecific binding to the polyclonal anti-N. meningitidis antibody correlating to approximately 25% of the signal obtained through specific binding. Minimal signal intensities could also be seen for two peptides of NGO1429 for the anti-E. coli antibody correlating to maximal 10% of the signal obtained through specific binding.

(TIF)

S2 Fig. Specificity controls of the identified peptides with epitope features of the remaining polypeptides. A) NGO1656, B) NGO1852, C) NGO2094, D) the first three potential epitopes NGO2095, E) further two potential epitopes NGO2095. Almost all peptides showed specific binding for anti-N. gonorrhoeae antibodies. Only two peptides of NGO2095 showed signal intensities for the anti-N. meningitidis antibody correlating to approximately 10% of the signal obtained through specific binding.

(TIF)

S3 Fig. Alanine scans of the identified epitopes of A) NGO0326_1_5, B) NGO0564_1_1, C) NGO0564_1_23, D) NGO0592_1_3, E) NGO0777_1_6. The boxes embody 50% of the values, while the whiskers comprise 98% of the data. Outliers are marked with a small x. Median values are indicated as a horizontal line, while the mean values are marked by a small square. Myelin basal protein (MBP) and rabbit Immunoglobulin G (IgG) were included as negative (red) and positive (green) controls. Boxes of substituted amino acids causing considerable signal drops compared to the remaining peptides are coloured in orange.

(TIF)

S4 Fig. Alanine scans of the identified epitopes of A) NGO1429_1_3, B) NGO1429_3_7, C) NGO1577_1_2, D) NGO1577_1_9, E) NGO1852_1_4. The boxes embody 50% of the values, while the whiskers comprise 98% of the data. Outliers are marked with a small x. Median values are indicated as a horizontal line, while the mean values are marked by a small square. Myelin basal protein (MBP) and rabbit Immunoglobulin G (IgG) were included as negative (red) and positive (green) controls. Boxes of substituted amino acids causing considerable...
signal drops compared to the remaining peptides are coloured in orange.

(TIF)

**S5 Fig.** Alanine scans of the identified epitopes of A) NGO2094_1_3c, B) NGO2094_1_10c, C) NGO2095_1_1, D) NGO2095_2_3c, E) NGO2095_2_13c, F) NGO2095_4_10. The boxes embody 50% of the values, while the whiskers comprise 98% of the data. Outliers are marked with a small x. Median values are indicated as a horizontal line, while the mean values are marked by a small square. Myelin basal protein (MBP) and rabbit Immunoglobulin G (IgG) were included as negative (red) and positive (green) controls. Boxes of substituted amino acids causing considerable signal drops compared to the remaining peptides are coloured in orange.

(TIF)

**S6 Fig.** Alanine scan of the identified epitope of NGO0170_1_3. The first and the last peptide are marked by a minus. The first peptide is additionally marked by a 1. The first fifteen spots correspond to the epitope sequence LLAREKIAAGATETI where each amino acid is substituted subsequently and each peptide is immobilised consecutively on one of the spots on the membrane. Spot 16 is the epitope peptide without substitution. Spot 17 a random peptide TESYLQASARMQQQ as negative control. Peptide spots 4 to 6 and 11 to 15 showed a dark staining comparable to the epitope peptide (spot 16) while peptides 1 to 3 and 7 to 10 showed a weaker staining. Spot 17 only showed a slight background stain.

(TIF)

**Author Contributions**

Conceptualization: MvNR FFB.

Data curation: DOC.

Formal analysis: DOC LD.

Funding acquisition: MvNR FFB.

Investigation: DOC LD.

Methodology: DOC SH.

Project administration: DOC SH.

Supervision: MvNR FFB.

Validation: DOC.

Writing – original draft: DOC LD SH.

**References**

1. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier Health Sciences; 2014.

2. Pariser H. Asymptomatic gonorrhea. Cutis. 1976; 17: 723–726. PMID: 828089

3. Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic Gonorrhea in Men. N Engl J Med. 1974; 290: 117–123. https://doi.org/10.1056/NEJM197401172900301 PMID: 4202519

4. WHO. WHO | Global incidence and prevalence of selected curable sexually transmitted infections–2008 [Internet]. 2008 [cited 17 Jun 2014]. Available: http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/
5. WHO. Sexually transmitted infections (STIs) [Internet]. 2015 [cited 5 Jul 2016]. Available: http://www.who.int/mediacentre/factsheets/fs110/en/

6. CDC. Reported STDs in the United States, 2014 [Internet]. 2014 [cited 7 Jul 2016]. Available: https://www.cdc.gov/std/stats14/std-trends-508.pdf

7. Holmes K. Sexually Transmitted Diseases, Fourth Edition. McGraw-Hill Education; 2008.

8. T Jw, L Ea, T C, D B, L Sd, K Lj, et al. High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Sex Transm Dis. 1994; 22: 310–311.

9. Tanaka M, Nakayama H, Harakoa M, Saika T, Kobayashi I, Naito S. Antimicrobial Resistance of Neisseria gonorrhoeae and High Prevalance of Ciprofloxacin-Resistant Isolates in Japan, 1993 to 1998. J Clin Microbiol. 2000; 38: 521–525. PMID: 10655338

10. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009; 22: 67–91. https://doi.org/10.1097/QCO.0b013e328320a836 PMID: 19532086

11. Unemo M, del Rio C, Shafer WM. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr. 2016; 4. https://doi.org/10.1128/microbiolspec.EI10-0009-2015 PMID: 27337478

12. CDC. Gonococcal Infections—2015 STD Treatment Guidelines [Internet]. 2015 [cited 14 Jul 2016]. Available: http://www.cdc.gov/std/tg2015/gonorrhea.htm

13. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013; 24: 85–92. https://doi.org/10.1177/0956462412472837 PMID: 24400344

14. Connor DO, Zantow J, Hust M, Bier FF, von Nickisch-Rosenegk M. Identification of Novel Immunogenic Proteins of Neisseria gonorrhoeae by Phage Display. PLoS ONE. 2016; 11. https://doi.org/10.1371/journal.pone.0149896 PMID: 26896666

15. Irving MB, Pan O, Scott JK. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol. 2001; 5: 314–324. https://doi.org/10.1016/S1367-5931(00)00208-8 PMID: 11479124

16. Yang H-J, Zhang J-Y, Wei C, Yang L-Y, Zuo Q-F, Zhuan Y, et al. Immunisation With Immunodominant Linear B Cell Epitopes Vaccine of Manganese Transport Protein C Confers Protection against Staphylococcus aureus Infection. PLoS ONE. 2016; 11. https://doi.org/10.1371/journal.pone.0149638 PMID: 26895191

17. Hoppe S, Bier FF, von Nickisch-Rosenegk M. Identification of Antigenic Proteins of the Nosocomial Pathogen Klebsiella pneumoniae. PLoS ONE. 2014; 9. https://doi.org/10.1371/journal.pone.0110703 PMID: 25333290

18. Song K-Y, Zhao H, Li S-H, Li X-F, Deng Y-Q, Wang H-J, et al. Identification and characterization of a linearized B-cell epitope on the pr protein of dengue virus. J Gen Virol. 2013; 94: 1510–1516. https://doi.org/10.1099/vir.0.052084-0 PMID: 23599476

19. Pinkett HW, Lee AT, Lum P, Locher KP, Rees DC. An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science. 2007; 315: 373–377. https://doi.org/10.1126/science.1135488 PMID: 17192991

20. Kovach AR, Hoff KE, Canty JT, Orans J, Brennan RG. Recognition of U-rich RNA by Hfq from the Gram-positive pathogen Listeria monocytogenes. RNA N Y N. 2014; 20: 1548–1559. https://doi.org/10.1261/rna.044032.113 PMID: 25150227

21. Wang J, Nemeria NS, Chandra sekhar K, Kumaran S, Arjunan P, Reynolds S, et al. Structure and Function of the Catalytic Domain of the Dihydrolipoyl Acetyltransferase Component in Escherichia coli Pyruvate Dehydrogenase Complex. J Biol Chem. 2014; 289: 15215–15230. https://doi.org/10.1074/jbc.M113.544080 PMID: 24742683

22. Ferbitz L, Maier T, Patzelt H, Bukau B, Deuerling E, Ban N. Trigger factor in complex with the ribosome forms a molecular cradle for nascent proteins. Nature. 2004; 431: 590–596. https://doi.org/10.1038/nature02899 PMID: 15334087

23. Swinger KK, Lemberg KM, Zhang Y, Rice PA. Flexible DNA bending in HU-DNA cocrystal structures. EMBO J. 2003; 22: 3749–3760. https://doi.org/10.1093/emboj/cdg351 PMID: 12853489

24. Kim DH, Im H, Jee JG, Jang SB, Yoon HJ, Kwon AR, et al. β-Arm flexibility of HU from Staphylococcus aureus dictates the DNA-biriding and recognition mechanism. Acta Crystallogr D Biol Crystallogr. 2014; 70: 3273–3289. https://doi.org/10.1107/S1399004714023931 PMID: 25478485

25. Qi R, Sarbeng EB, Liu Q, Le KQ, Xu X, Xu H, et al. Allosteric opening of the polypeptide-binding site when an Hsp70 binds ATP. Nat Struct Mol Biol. 2013; 20: 900–907. https://doi.org/10.1038/nsmb.2583 PMID: 23708608

26. Cordeiro AT, Cáceres AJ, Vertommen D, Concepción JL,Michels PAM, Verséès W. The Crystal Structure of Trypanosoma cruzi Glucokinase Reveals Features Determining Oligomerization and Anomer
46. Benkert P, Schwede T, Tosatto SC. QMEANclust: estimation of protein model quality by combining a composite scoring function with structural density information. BMC Struct Biol. 2009; 9: 35. https://doi.org/10.1186/1472-6807-9-35 PMID: 19457232

47. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990; 215: 403–410. https://doi.org/10.1016/S0022-2836(05)80360-2 PMID: 2231712